← Beam Therapeutics Inc. (BEAM) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Beam Therapeutics Inc. (BEAM)
Biological Products, (No Diagnostic Substances) · market cap $2.6B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
4
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Beam Therapeutics (BEAM) is a Cambridge-based gene-editing company with 341 employees and a ~$3.2B market cap, developing base-editing and prime-editing therapies across four Phase 2 programs covering sickle cell disease, T-cell lymphoblastic lymphoma, glycogen storage disease type Ia, and alpha-1 antitrypsin deficiency. The company reported a positive Phase 1 signal in June 2026 and carries a critical 6.7-month cash runway against $288M in cash, creating near-term financing pressure.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · BEAM-201imp 7/10
- 2027-06-15 (est.)Phase 2 · BEAM-302imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BEAM-101 | Phase 2 | Sickle Cell Disease |
| BEAM-201 | Phase 2 | Lymphoblastic Lymphoma |
| BEAM-301: Single dose of BEAM-301 administered by IV | Phase 2 | Glycogen Storage Disease Type Ia |
| BEAM-302 | Phase 2 | Alpha 1-Antitrypsin Deficiency |
Price & technical context
3-month
-29.9%
6-month
+0.7%
12-month
+0.5%
52-wk range
$20.60–$37.92
vs 50-day MA
-8.3%
vs 200-day MA
-14.4%
Realized vol
72.1%
Max drawdown
-57.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BEAM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.